metabolised to dihomo-y-linolenic acid (DGLA), which produces the monoenoic PGs, e.g., PGEI.V PGE1 has been shown to have important antiinflammatory effects.5 DGLA cannot itself be converted to LTs but can form a 15- Again, animal studies have suggested that an antiinflammatory effect can be obtained by increasing dietary EPA.12 13 The effect of altering EFAs in the diet of humans with inflammatory disorders has, however, been less well studied. Wright and Burton have shown a significant clinical improvement in the manifestation of eczema in patients treated with EPO,'4 and Baker, Krakauer, and Zurier have demonstrated a reduction in human synovial cell proliferation in vitro by addition of DGLA. 5 Two clinical studies of EPO in rheumatoid arthritis (RA) proved disappointing.'6 17 The respective doses of EPO were low and the study periods short, however.
Payan et al have shown a decrease in leucocyte activity in humans after treatment with EPA,'0 and Kremer et al suggested that patients with RA had obtained benefit after such treatment. '8 Another benefit might be expected from manipulating essential fatty acids in the diet of patients with RA. 'First line' treatment for RA is with nonsteroidal anti-inflammatory drugs (NSAIDs). These drugs act by inhibiting the cyclo-oxygenase enzyme and therefore decreasing the production of proinflammatory prostaglandins from AA. AA, however, is also metabolised by another enzyme, the lipoxygenase enzyme, into the LTs.3 Treatment with NSAIDs may therefore ameliorate the PG mediated aspects of inflammation, but will allow those dependent on lipoxygenase action to proceed unchecked. Furthermore, NSAIDs may produce side effects, e.g., gastric irritation, as a result of decreased PG production. Theoretically it should be possible to substitute EPO or EPA for NSAID treatment; this would allow a decrease in the proinflammatory PGs and LTs metabolised from AA and, as other less inflammatory PGs (e.g., PGEI) would be increased, there should be no gastric side effects from this therapy.
The aim of our study, therefore, was to determine whether EPO or an EPO/fish oil combination containing EPA could be substituted for NSAID therapy without any deterioration in clinical symptoms. The study was double blind and placebo controlled.
Patients and methods

PATIENTS
Forty nine patients with classical or definite RA as defined by American Rheumatism Association criteria were enrolled in the study after informed consent had been obtained. Permission for the study had been received from the regional ethical committee. All patients required first line (NSAID) therapy for control of their symptoms, but none was considered severe enough to warrant second line therapy. Sixteen patients received EPO treatment taken as 12 capsules/day, providing a total daily dose of 540 mg GLA; 15 received EPO/fish oil capsules (12/day), providing a total daily dose of 450 mg GLA and 240 mg EPA; 18 patients received 12 capsules/day of placebo (liquid paraffin). In addition, all capsules contained vitamin E as an antioxidant (dose 120 mg/day). As it was considered that 12 capsules at one time might be inconvenient the patients were instructed to take them intermittently throughout the day. Most selected four capsules three times/day, though some patients took six twice/day or three capsules four times/day.
CAPSULES
All three types of capsules were supplied by Efamol Ltd and were visually identical. They were issued to the patients in a randomised double blind fashion.
STUDY DESIGN
The duration of study was 15 months. For the first three months of the study the patients were instructed to take the 12 capsules of oil a day, plus their full dose of NSAID. From three to six months in particular, but also up to 12 months, the patients were instructed to decrease or stop their NSAID. From 12 to 15 months they were told to maintain, if possible, the current dose of NSAID. Patients were only to decrease or stop NSAIDs if this could be done without exacerbation of RA symptoms. At 12 months all patients received placebo capsules (12/day) without vitamin E. As this was part of the study design investigators were aware of the treatment in all patients from 12 to 15 months; the patients, however, remained blinded. The aim of this placebo phase was to assess whether any improvement was due to the antioxidant and radical scavenging effect of the vitamin E,19 and also to monitor relapse. The patients attended the clinic at monthly intervals for the first six months and thereafter at three-monthly intervals.
CLINICAL ASSESSMENT
Full metrological assessment was carried out before the start of the study and at 3, 6, 12, and 15 months.
again at 3, 6, 12, and 15 months. The erythrocyte sedimentation rate (ESR) was measured, as were C reactive protein (CRP) levels. Haemoglobin (Hb) and rheumatoid factor estimation were also carried out. Samples from month 0, 6 months, and 12 months were stored at -70°C for later analysis of plasma and red cell membrane EFA levels; this enabled a check of patient compliance.
STATISTICAL ANALYSES
Comparability between the treatment groups was analysed with the Mann-Whitney U test. Sequential analyses were carried out using the two tailed paired Wilcoxon test.
Results Table 1 shows the comparability of the different treatment groups, both for clinical and laboratory measurements, at the start of the study. No significant differences in the patient populations were witnessed. Table 2 shows the number of patients withdrawn from the study by 12 months. One patient in the EPO group and two in the EPO/fish oil group were withdrawn owing to increasing symptoms of RA, compared with 10/18 of the placebo patients (both p<0-001, Mann-Whitney).
The results from all patients who were withdrawn were analysed throughout the study on an intention to treat basis. The subsequent results are expressed as a percentage of baseline so that the different group totals can be more easily compared. Four patients experienced side effects. Two in the EPO group, one with nausea and one with diarrhoea, required to be withdrawn from the study at two and one months respectively (Table 2) . Two patients in the EPO/fish oil group also experienced side effects, nausea and headache, but neither patient required to be withdrawn from the study.
Estimation of fatty acid levels by high performance liquid chromatography in plasma and red cell membranes confirmed compliance in all subjects apart from one EPO/fish oil patient. This patient was one of the two from the group who were withdrawn because of increasing RA symptoms.
Discussion
There are good theoretical reasons for suggesting that altering dietary EFA may produce anti-inflammatory effects similar to cyclo-oxygenase inhibition by NSAIDs.5 7 9 13 Indeed, additional effects might be expected because of the alteration in leucotriene production not seen with NSAIDs.6 Furthermore, fewer gastric side effects would be expected as PGs of other series, though less inflammatory, would be available for gastric cytoprotection. 5 In this study we have shown that it was possible for some patients with RA to decrease or stop NSAID treatment when EPO or EPO/fish oil was given. This was achieved with no deterioration in clinical or laboratory measures of RA activity. A decrease in NSAID dose was also seen in the placebo group, though this was much less marked. In combination with the 30% placebo subjective response, this stresses the importance of placebo controlled studies in RA. Four patients (three placebo and one EPO) were not receiving any NSAID at the start of the study. These patients had stopped NSAID treatment without medical advice, having developed dyspepsia since their last clinic visit. Because of the severity of the gastrointestinal symptoms it was decided to enrol them into the study.
It was interesting that, despite the lack of objective improvement in symptoms on the active oils, there was a very definite subjective improvement. The mechanism of this is unclear, but two alternative explanations are possible. EPO has had some success in treating premenstrual tension and certainly it is known to alter brain PG production.21 22 PGE, may have an antidepressant effect,23 and the increase in PGE, after EPO treatment may be responsible for the subjective response witnessed in 4 Subjective response in the three groups ofpatients.
Hansen et al. 17 Both these studies used a lower dosage regimen of EPO and in both the study period was only three months. As can be seen from our data, improvement is most marked from six months onwards. In addition, their patients stopped NSAIDs abruptly before the start of the studies. This may have caused a flare in the patients' symptoms in the first weeks as it is unclear how long EFA treatment should be undertaken before alteration in PG and LT production occurs. This combination of NSAID withdrawal and short treatment period may explain the authors' negative findings. It is also possible that these two studies looked at different patient populations. All of our patients had mild RA as shown by the clinical and laboratory values in Table 1 . In contrast, these other Kremer et al showed benefit in RA with EPA treatment'8; our work cannot be compared with this study, however, as we used EPA only in combination with EPO. Nevertheless, he did show an improvement at three months and certainly this agrees with our data, where the combined therapy did seem to produce an earlier response. There did not, however, appear to be any other differences between the EPO and the EPO/fish oil groups. It is possible that the addition of EPA had no effect and the lower dose of EPO was sufficient to allow NSAID withdrawal; it is also possible that the fish oil contributed to the effect of the EPOs, thus making the two groups indistinguishable. In retrospect a more suitable study design would appear to have been EPO versus fish oil versus placebo; previous work, however, had suggested a synergism between the two EFAs24 which we wished to investigate.
In conclusion, therefore, we have shown that it is possible to decrease or stop NSAIDs in some patients with RA by introducing EPO or EPO/fish oil treatment. It should be noted, however, that, although the patients claimed a subjective improvement, there was no change in any of the measurements conventionally used to measure disease activity. It is unlikely, therefore, that long term therapy with these EFAs would alter the course or prognosis of the disease. It would seem that these oils may be best used in clinical situations where NSAID therapy should be avoided, for example in patients with peptic ulceration or renal impairment.
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